Ocular Therapeutix, Inc. (OCUL)
8.74
-0.17
(-1.91%)
USD |
NASDAQ |
Apr 16, 15:02
Ocular Therapeutix Research and Development Expense (Quarterly) : 50.80M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| EyePoint Plc | 59.21M |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Vertex Pharmaceuticals, Inc. | 973.70M |
| ACADIA Pharmaceuticals, Inc. | 84.76M |
| Rhythm Pharmaceuticals, Inc. | 42.03M |